IFNβ and glatiramer acetate trigger different signaling pathways to regulate the IL-1 system in multiple sclerosis

References

• Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 2006; 20:879 - 896
   PubMed Web of Science ®Google Scholar
• Arend WP, Palmer G, Gabay C. IL-1, IL-18 and IL-33 families of cytokines. Immunol Rev 2008; 223:20 - 38
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the inter-leukin-1-receptor antagonist. N Engl J Med 2009; 360:2426 - 2437
   PubMed Web of Science ®Google Scholar
• Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995; 37:424 - 435
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs. Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903 - 914
   PubMed Web of Science ®Google Scholar
• Molnarfi N, Gruaz L, Dayer JM, Burger D. Opposite effects of IFNbeta on cytokine homeostasis in LPS- and T cell contact-activated human monocytes. J Neuroimmunol 2004; 146:76 - 83
   PubMed Web of Science ®Google Scholar
• Burger D, Molnarfi N, Weber MS, Brandt KJ, Benkhoucha M, Gruaz L, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci USA 2009; 106:4355 - 4359
   PubMed Web of Science ®Google Scholar
• Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997; 8:345 - 349
   PubMed Web of Science ®Google Scholar
• Jungo F, Dayer JM, Modoux C, Hyka N, Burger D. IFNbeta inhibits the ability of T lymphocytes to induce TNFalpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001; 14:272 - 282
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Patti F, DiMarco R, Zaccone P, Nicoletti A, Meroni P, et al. Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFNbeta treatment. Cytokine 1996; 8:395 - 400
   PubMed Web of Science ®Google Scholar
• Perini P, Tiberio M, Sivieri S, Facchinetti A, Biasi G, Gallo P. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a. Eur Cytokine Netw 2000; 11:81 - 86
   PubMed Web of Science ®Google Scholar
• Comabella M, Julia E, Tintore M, Brieva L, Tellez N, Rio J, et al. Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis. J Neurol 2008; 255:1136 - 1141
   PubMed Web of Science ®Google Scholar
• Carpintero R, Brandt KJ, Gruaz L, Molnarfi N, Lalive PH, Burger D. Glatiramer acetate triggers PI3K{delta}/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes. Proc Natl Acad Sci USA 2010; 107:17692 - 17697
   PubMed Web of Science ®Google Scholar
• Brandt KJ, Carpintero R, Gruaz L, Molnarfi N, Burger D. A novel MEK2/PI3K{delta} pathway controls the expression of IL-1 receptor antagonist in IFN{beta}-activated human monocytes. J Leukoc Biol 2010; 88:1191 - 1200
   PubMed Web of Science ®Google Scholar
• Molnarfi N, Brandt KJ, Gruaz L, Dayer JM, Burger D. Differential regulation of cytokine production by PI3Kδelta in human monocytes upon acute and chronic inflammatory conditions. Mol Immunol 2008; 45:3419 - 3427
   PubMed Web of Science ®Google Scholar
• Pan CQ, Liou YC, Low BC. Active Mek2 as a regulatory scaffold that promotes Pin1 binding to BPGAP1 to suppress BPGAP1-induced acute Erk activation and cell migration. J Cell Sci 2010; 123:903 - 916
   PubMed Web of Science ®Google Scholar
• Molnarfi N, Hyka-Nouspikel N, Gruaz L, Dayer JM, Burger D. The production of IL-1 receptor antagonist in IFN-{beta}-stimulated human monocytes depends on the activation of phosphatidylinositol 3-kinase but not of STAT1. J Immunol 2005; 174:2974 - 2980
   PubMed Web of Science ®Google Scholar